双盲同行评审对肺科、重症与睡眠医学期刊的因果效应评估
该研究以 CHEST(2022年7月改用双盲同行评审)为干预组、Annals of the American Thoracic Society(AATS,同期维持单盲评审)为对照,纳入2020年1月至2024年间送审稿件4,651篇(CHEST 3,494篇,AATS 1,157篇),采用三重交互项多变量回归估计双盲评审对稿件接受率的因果效应。共同主要暴露为第一作者和最后作者性别,次要暴露为作者居住于英语流利国家。校正后,双盲评审对女性与男性作者的接受率影响无差异(第一作者 -7.4 个百分点,95%CI -20.9 至 6.0,P=0.28;最后作者 -10.1 个百分点,95%CI -25.1 至 5.0,P=0.19);双盲评审对英语流利国家第一作者(而非最后作者)的接受率有负面影响(较非流利国家作者 -16.8 个百分点,95%CI -32.1 至 -1.6,P=0.030)。作者解读认为双盲评审未按性别差异影响作者,但按推定英语流利程度产生了差异影响。
要点
- CHEST 于2022年7月改用双盲同行评审,以同期维持单盲评审的 AATS 为对照,纳入2020年1月至2024年送审稿件4,651篇(CHEST 3,494篇,AATS 1,157篇)。
- 校正后双盲评审对第一作者接受率的影响在女性与男性间无差异:-7.4 个百分点(95%CI -20.9 至 6.0,P=0.28)。
- 校正后双盲评审对最后作者接受率的影响在女性与男性间无差异:-10.1 个百分点(95%CI -25.1 至 5.0,P=0.19)。
- 双盲评审对英语流利国家第一作者(较非流利国家)接受率有负面影响:-16.8 个百分点(95%CI -32.1 至 -1.6,P=0.030)。
- 2020至2024年 CHEST 较 AATS 女性第一作者比例更低(38.7% vs 45.5%,SMD 0.14)、英语流利国家第一作者比例更低(56.0% vs 77.7%,SMD 0.47),接受率更低(30.7% vs 48.4%,SMD 0.37)。
适用人群与场景
- 2020年1月至2024年期间投稿至 CHEST 和 Annals of the American Thoracic Society(AATS)并送同行评审的稿件,共4,651篇(CHEST 3,494篇,AATS 1,157篇),其中4,645篇(99.9%)可识别作者性别。
- 暴露变量包括第一作者和最后作者性别,以及作者居住于英语流利国家(次要暴露)。
研究设计与关键结果
- 研究设计:以 CHEST(2022年7月改用双盲同行评审)为干预组、AATS(同期维持单盲评审)为对照,采用三重交互项多变量回归模型估计双盲评审对稿件接受率的因果效应,协变量包括年份和主题。
- 2020至2024年 CHEST 较 AATS:女性第一作者38.7% vs 45.5%(SMD 0.14),女性最后作者23.9% vs 31.2%(SMD 0.16);英语流利国家第一作者56.0% vs 77.7%(SMD 0.47),英语流利国家最后作者57.9% vs 79.0%(SMD 0.47);接受率30.7% vs 48.4%(SMD 0.37)。
- 校正后双盲评审对接受率的影响在女性与男性第一作者间无差异:-7.4 个百分点(95%CI -20.9 至 6.0,P=0.28)。
- 校正后双盲评审对接受率的影响在女性与男性最后作者间无差异:-10.1 个百分点(95%CI -25.1 至 5.0,P=0.19)。
- 双盲评审对英语流利国家第一作者(较非流利国家)接受率有负面影响:-16.8 个百分点(95%CI -32.1 至 -1.6,P=0.030);对最后作者的影响原文未报告统计学显著性。
证据类型、等级与局限
- 证据类型:观察性研究,利用 CHEST 改为双盲评审这一自然实验,以 AATS 为对照,采用多变量回归模型估计因果效应。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,双盲同行评审未按性别差异影响作者接受率,但按推定英语流利程度产生了差异影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Double-blind peer review (DBPR; reviewers masked to author identities and vice versa) aims to reduce biases. The effectiveness of DBPR has not been studied in pulmonary, critical care, and sleep journals.
RESEARCH QUESTION: What was the causal effect on bias of DBPR at CHEST?
STUDY DESIGN AND METHODS: From January 2020 to June 2022, CHEST and Annals of the American Thoracic Society (AATS) used single-blind peer review (reviewers concealed from authors only); in July 2022, CHEST switched to DBPR. We estimated the causal effect of DBPR on manuscript acceptance at CHEST using AATS as a control. The co-primary exposures were first and last author gender; author residence in English-fluent countries was considered as a secondary exposure. To estimate DBPR's differential impact according to exposure, multivariable regression models were constructed with triple interaction terms (eg, author gender × CHEST vs AATS × pre- vs post-DBPR), all component factors (eg, author gender), paired interactions (eg, author gender × CHEST vs AATS), and covariables (year, topic).
RESULTS: The study included 4,651 manuscripts (CHEST, 3,494; AATS, 1,157) sent for peer review; 4,645 (99.9%) had identifiable author gender. From 2020 to 2024, CHEST submissions (compared with AATS) were less frequently authored by women (first, 38.7% vs 45.5% [standardized mean difference (SMD), 0.14]; last, 23.9% vs 31.2% [SMD, 0.16]) or people from English-fluent countries (first, 56.0% vs 77.7% [SMD, 0.47]; last, 57.9% vs 79.0% [SMD, 0.47]), and acceptance rates were lower (30.7% vs 48.4%; SMD, 0.37). Following adjustment, no difference was appreciated in the impact of DBPR on acceptance for women vs men authors (first, -7.4 [95% CI, -20.9 to 6.0] percentage points [P = .28]; last, -10.1 [95% CI, -25.1 to 5.0] percentage points [P = .19]). DBPR negatively affected first (but not last) authors from English-fluent countries (vs non-fluent, -16.8 [95% CI, -32.1 to -1.6] percentage points; P = .030).
INTERPRETATION: Our results show that DBPR did not differentially affect authors by gender but did by presumed English fluency.
参考来源
- Gershengorn HB, Vranas KC, Cooke CR, et al. Estimating the Causal Effect of Double-Blind Peer Review for a Pulmonary, Critical Care, and Sleep Medicine Journal. Chest. 2025. PMID: 39993593. doi:10.1016/j.chest.2025.02.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。